Search

Your search keyword '"Tisi, Maria Chiara"' showing total 329 results

Search Constraints

Start Over You searched for: Author "Tisi, Maria Chiara" Remove constraint Author: "Tisi, Maria Chiara"
329 results on '"Tisi, Maria Chiara"'

Search Results

1. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study

3. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

4. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

5. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

6. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

7. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

8. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL

9. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

10. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

11. Secondary primary malignancies after CD‐19 directed CAR‐T‐cell therapy in lymphomas: A report from the Italian CART‐SIE study.

12. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

13. A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report

14. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

15. Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper

16. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

17. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

18. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

19. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

20. Health-Related Quality of Life Profile and Symptom Burden of Patients with Aggressive B-Cell Lymphomas Just before CAR-T-Cell Therapy: A Real-World Study By the Gimema

21. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

22. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi

23. S231: PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY

24. S228: POSITRON EMISSION TOMOGRAPHY EVALUATION IN A LARGE GROUP OF PATIENTS AFFECTED BY RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH ANTI-19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY (CART SIE).

25. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

27. COVID-19 in adult acute myeloid leukemia patients:a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

28. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

29. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

30. COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)

31. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

32. Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

33. PROSPECTIVE MULTICENTER STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME OF 230 UNFIT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING FIRST‐LINE THERAPY WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX

34. SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia

35. Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

36. Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

37. Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

38. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

39. IDH2 R172mutation in angioimmunoblastic T‐cell lymphoma: A retrospective multicenter case series

40. SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort

41. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

43. COVID-19 infection in adult patients with hematological malignancies:a European Hematology Association Survey (EPICOVIDEHA)

44. Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group

45. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

46. Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study)

47. COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)

48. Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project

49. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

50. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Catalog

Books, media, physical & digital resources